Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Ablation + Chemo for Colorectal Cancer Metastases
NCT04888806Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in colorectal cancer (CRC), sponsored by Harbin Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04888806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888806.